Yurii Sh. Khalimov

Yurii Sh. Khalimov

Auto-generated profile, based on publicly available information

Yurii Sh. Khalimov

Pavlov First Saint Petersburg State Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
ИДИван Иванович Дедов
Иван Иванович Дедов
MSMarina Shestakova
Marina Shestakova
AMAlexander Y. Mayorov
Alexander Y. Mayorov
MSMinara S. Shamkhalova
Minara S. Shamkhalova
OSOlga Yu. Sukhareva
Olga Yu. Sukhareva
ЮХЮрий Шавкатович Халимов
Юрий Шавкатович Халимов
Сахарный диабет 2 типа у взрослых

19 February 2022 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
IDI. I. Dedov
I. I. Dedov
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
GMG. A. Melnichenko
G. A. Melnichenko
RRR. V. Rozhivanov
R. V. Rozhivanov
AKArmais Kamalov
Armais Kamalov
ЮХЮ. Ш. Халимов
Ю. Ш. Халимов
Hypogonadism in males, defined as a decrease in serum testosterone levels in combination with characteristic symptoms and/or signs, can be observed with pathological changes in the testicles and/or pituitary gland, such as Klinefelter’s syndrome, Kallman’s syndrome, as well as in men with metabolic (obesity, diabetes mellitus) or iatrogenic disorders leading to a decrease in androgen production. The draft guidelines cover the extensive range of pathologies that cause hypogonadism development (testosterone deficiency) and focus on its clinical variants, which make up the majority of cases of hypogonadism observed in men. The authors and reviewers are an interdisciplinary group of experts, consisting of endocrinologists, andrologists, urologists - members of the «Russian Association of Endocrinologists» and «Men’s and Reproductive Health» public organizations.Clinical guidelines contain the most reliable evidence available to experts at the time of writing. Nevertheless, recommendations cannot replace clinical experience, and deciding on the start of treatment, choosing a method of therapy, or a drug should always consider the individual characteristics of a specific patient.

24 February 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
VMV. I. Mazurov
V. I. Mazurov
AMA. I. Martynov
A. I. Martynov
ENE. L. Nasonov
E. L. Nasonov
SSS. A. Saiganov
S. A. Saiganov
ЮХЮ. Ш. Халимов
Ю. Ш. Халимов
Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике

15 July 2025 in Bulletin of Reproductive Health
Verified
Journal Article
Open access
PDF file
IDI. I. Dedov
I. I. Dedov
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
GMG. A. Melnichenko
G. A. Melnichenko
ETEkaterina Troshina
Ekaterina Troshina
NMN. V. Mazurina
N. V. Mazurina
ЮХЮ. Ш. Халимов
Ю. Ш. Халимов
Клинические рекомендации «Ожирение» Минздрава России. Версия 2024 года

22 June 2020 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
ИДИван Иванович Дедов
Иван Иванович Дедов
MSMarina Shestakova
Marina Shestakova
AMAlexander Y. Mayorov
Alexander Y. Mayorov
MSMinara S. Shamkhalova
Minara S. Shamkhalova
ТНТатьяна Васильевна Никонова
Татьяна Васильевна Никонова
ЮХЮрий Шавкатович Халимов
Юрий Шавкатович Халимов
Сахарный диабет 1 типа у взрослых

13 January 2021 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
VSVladimir V Salukhov
Vladimir V Salukhov
YKYurii Sh. Khalimov
Yurii Sh. Khalimov
СШСергей Борисович Шустов
Сергей Борисович Шустов
SPSergey I. Popov
Sergey I. Popov
ЮХЮрий Шавкатович Халимов
Юрий Шавкатович Халимов
Type 2 diabetes mellitus (T2DM) is the cause of the development of diabetic nephropathy — a complication that determines the high degree of disability and mortality of such patients. Until recently, approaches to normalizing glucose levels did not have a significant possibility of influencing the outcome of kidney damage in diabetes. Type 2 sodium glucose cotransporter inhibitors (SGLT2) are a new class of glucose-lowering drugs that improve glycemic control due to an insulin-independent mechanism of action associated with increased urinary glucose excretion. The review provides an analysis of the results of studies on the assessment of nephroprotective actions — one of the pleiotropic actions of this drugs group. These materials show the properties of SGLT2 inhibitors to reduce the risk of developing and the progression of albuminuria, to save glomerular filtration rate, to reduce the frequency of end-stage renal disease and the need for renal replacement therapy in patients with T2DM. The article gives and analyzes the currently existing hypotheses of the mechanism of action of these glucose-lowering drugs. The risk of the most common renal complications with the use of SGLT2 inhibitors is considered. The practical aspects of the use of SGLT2 inhibitors in modern algorithms for the care of patients with T2DM are indicated, as well as the prospects for new randomized clinical trials.